A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

While antipsychotics can be effective for some patients, they come with well-known side effects, including an increased risk ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

Treatment for depression could be revolutionised with new and more effective drug options thanks to a breakthrough involving ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.